Physalin B shows antimalarial, anti-Trypanosoma cruzi, anti-bacterial, anti- leukemia activities, it has the potential to be developed as an effective chemotherapeutic lead compound for the treatment of malignant melanoma, it inhibits androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression.

The antimalarial activities of Physalin B, physalin D, physalin F, and physalin G (1-4), isolated from Physalis angulata, were investigated. In silico analysis using the similarity ensemble approach (SEA) database predicted the antimalarial activity of each of these compounds, which were shown using an in vitro assay against Plasmodium falciparum. However, treatment of P. berghei-infected mice with 3 increased parasitemia levels and mortality, whereas treatment with 2 was protective, causing a parasitemia reduction and a delay in mortality in P. berghei-infected mice[1]

23133-56-4

C28H30O9

510.53

酸浆苦味B

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years